A new study by researchers at the Perelman School of Medicine at the University of Pennsylvania suggests that cardiovascular disease may be an unfortunate consequence of mammalian evolution. The study, published in a recent issue of the journal Blood, demonstrates that the same features of blood platelets that may have provided an evolutionary advantage to early mammals now predispose humans to cardiovascular disease.
“The biology of platelets has been studied in great detail in the context of human disease, but almost nothing is known about why mammals have platelets, whereas no other species do,” said lead study author Alec A. Schmaier, PhD, an MD/PhD student in the lab of Mark Kahn, MD, professor of Medicine at Penn. “This new line of research suggests that platelets could have allowed mammals to better survive traumatic injury by being able to form cellular clots in arterial blood vessels. The price for this evolutionary change may be modern cardiovascular diseases.”
Platelets are small circulating cells that have no nucleus and form clots at sites of vessel injury. Platelets are required to prevent excessive bleeding following traumatic injury, but they also form clots at sites of atherosclerotic plaques in the blood vessels that lead to stroke and heart attack. Drugs that inhibit the function of platelets, including aspirin and clopidogrel, are the main weapons for treating heart attack and stroke.
Despite being a vital element of the blood clotting system, platelets are only found in mammals, whereas all non-mammalian vertebrates, including birds, have thrombocytes. About twice the diameter of platelets, thrombocytes contain a nucleus. Studies performed in the 1970s suggested they have a clotting function similar to platelets, but extensive studies of thrombocytes using modern experimental techniques have not been performed.
The research team focused their study on birds (compared to fish or reptiles for example) because birds and mammals both have a high pressure arterial system. Birds in fact have higher cardiac output and blood pressures than mammals do. Therefore, the challenge for hemostasis, i.e. blood clotting after vessel injury or trauma, should be similar between a mammal and a bird. However, in the present study, using molecular and physiologic techniques, the Penn researchers discovered that avian thrombocytes express most of the same proteins as platelets, with two key exceptions: thrombocytes express a significantly lower level of one essential platelet protein (the fibrinogen receptor) and are completely deficient in another (the adenosine diphosphate receptor) that function in a pathway required to form occlusive clots in the arterial system and are the primary targets of anti-platelet medications. In collagen flow-chamber experiments, the research team found that thrombocytes could not form 3-dimensional aggregates under high-flow conditions, a key step in the pathogenesis of stroke and heart attack.
Collaborative studies with colleagues at Penn's School of Veterinary Medicine, Karen Rosenthal, DVM, MS, and Jeff Runge, DVM, and Tim Stalker, in Department of Medicine –Hematology/Oncology, at the Perelman School of Medicine, next compared the ability of platelets and thrombocytes to form intra-vascular clots in mice and similarly sized parakeets. The mice, but not the birds, developed clots that prevented blood flow after arterial injury due to the ability of platelets, but not thrombocytes, to stick to each other under high flow conditions.
Although the researchers caution that this prediction cannot be tested in all contexts, the finding that equivalent degrees of arterial vessel wall injury in vessels of similar size and equal hemodynamic forces result in the occlusion in mammals but not in birds is consistent with the hypothesis that platelets mediate a more efficient clotting response than thrombocytes.
Dr. Kahn, the study’s senior author, concluded, “Although the reason for platelet evolution in mammals can never be known with certainty, it is tempting to speculate that platelets may have allowed early mammals to better survive trauma and thereby provided a survival advantage.”
The research was supported by National Institute of Health and by an American Heart Association (AHA) postdoctoral fellowship.
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4 billion enterprise.
Penn's Perelman School of Medicine is currently ranked #2 in U.S. News & World Report's survey of research-oriented medical schools and among the top 10 schools for primary care. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $507.6 million awarded in the 2010 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top 10 hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; and Pennsylvania Hospital – the nation's first hospital, founded in 1751. Penn Medicine also includes additional patient care facilities and services throughout the Philadelphia region.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2010, Penn Medicine provided $788 million to benefit our community.
Jessica Mikulski | Newswise Science News
Self-organising system enables motile cells to form complex search pattern
07.05.2019 | Westfälische Wilhelms-Universität Münster
Mouse studies show minimally invasive route can accurately administer drugs to brain
02.05.2019 | Johns Hopkins Medicine
Engineers at the University of Tokyo continually pioneer new ways to improve battery technology. Professor Atsuo Yamada and his team recently developed a...
With a quantum coprocessor in the cloud, physicists from Innsbruck, Austria, open the door to the simulation of previously unsolvable problems in chemistry, materials research or high-energy physics. The research groups led by Rainer Blatt and Peter Zoller report in the journal Nature how they simulated particle physics phenomena on 20 quantum bits and how the quantum simulator self-verified the result for the first time.
Many scientists are currently working on investigating how quantum advantage can be exploited on hardware already available today. Three years ago, physicists...
'Quantum technologies' utilise the unique phenomena of quantum superposition and entanglement to encode and process information, with potentially profound benefits to a wide range of information technologies from communications to sensing and computing.
However a major challenge in developing these technologies is that the quantum phenomena are very fragile, and only a handful of physical systems have been...
Working group led by physicist Professor Ulrich Nowak at the University of Konstanz, in collaboration with a team of physicists from Johannes Gutenberg University Mainz, demonstrates how skyrmions can be used for the computer concepts of the future
When it comes to performing a calculation destined to arrive at an exact result, humans are hopelessly inferior to the computer. In other areas, humans are...
Scientists develop a molecular recording tool that enables in vivo lineage tracing of embryonic cells
The beginning of new life starts with a fascinating process: A single cell gives rise to progenitor cells that eventually differentiate into the three germ...
29.04.2019 | Event News
17.04.2019 | Event News
15.04.2019 | Event News
22.05.2019 | Life Sciences
22.05.2019 | Life Sciences
22.05.2019 | Physics and Astronomy